Northeast Johnson County will be one of the locations for a new study aiming to get FDA approval for a new drug to treat Alzheimer’s for the first time since 2003.
The University of Kansas Alzheimer’s Disease Center in Fairway is seeking participants for a national study on an investigational medication for patients diagnosed with mild-to-moderate cases of Alzheimer’s disease. The drug is being examined for its potential to slow the progression of the disease, which affects more than five million Americans. KU’s Dr. Jeffrey Burns is the local investigator for the national NOBLE study.
Criteria for consideration for inclusion in the study follows:
Women and men with mild to moderate Alzheimer’s disease who:
- Are aged 55-85 years old
- Are stable on donepezil (Aricept®) or rivastigimine (Exelon® Patch) treatment
- Are living in the community (not in a nursing home)
- Have a study partner that has at least 10 hours of contact per week, who can attend study visits
- Weigh no more than 220 pounds
For more information about enrolling in the study, visit the NOBLE study website.